PUBLISHED May 28, 2026
The Headline and What Lies Beneath It
According to “Erhvervene forventer at øge investeringer i 2026 — Konjunkturbarometer for erhvervene”, published by Danmarks Statistik, Danish businesses entered 2026 with a cautiously positive outlook for investment — a shift from the investment decline that the industrial sector had been signaling through much of 2025. The broader economic data supports a picture of resilience: GDP grew by 1.9 percent in the first quarter of 2026, corrected for price developments and seasonal movements, and the year-on-year comparison shows GDP up 5.9 percent relative to the first quarter of 2025.
Those are impressive numbers by any European standard. But Danmarks Statistik’s own analysis is explicit about their interpretation. The first quarter growth was driven primarily by a large advance in industry — specifically the pharmaceutical sector. When the pharmaceutical industry is excluded, gross value added growth in the remaining economy was just 0.2 percent. The trade and transport sector provided additional support. But the underlying economy outside of pharma is expanding at a pace that would not look strong in any normal comparative context.
The Pharmaceutical Dependency: A Feature, Not a Bug
Denmark’s statistical peculiarity is well understood by economists who follow the country closely, but it bears explanation for readers approaching it for the first time. Denmark is home to some of the world’s largest pharmaceutical companies — most prominently Novo Nordisk, whose global revenues from diabetes and obesity treatments have grown explosively in recent years. These revenues flow into Danish national accounts in ways that can produce dramatic swings in measured GDP and exports that bear little relationship to the underlying condition of the domestic economy.
The pattern is consistent across recent Danish data. GDP growth for the full year 2025 was 2.9 percent — strong by European standards — but the pharmaceutical sector was again the dominant contributor. Danish national accounts for 2024 showed growth of 3.5 percent. Strip out pharmaceuticals, and growth would have been considerably more modest in both years. In 2022 and 2023, the national accounts showed marginal growth or near-stagnation — but without pharmaceuticals, growth would have been negative in both years.
This structural feature is neither a problem to be fixed nor a weakness to be hidden — it reflects a genuine competitive advantage in one of the world’s most valuable industries. But it does mean that Danish headline GDP figures require more careful interpretation than those of most comparable economies. When assessing the cyclical condition of the Danish economy — the state of consumption, construction, services, manufacturing outside pharma — the headline number is often misleading.
Businesses Plan to Invest More — With Caveats
The core finding of the Danmarks Statistik business barometer is that Danish firms expect to increase investment in 2026, after a period in which industrial investment had been running below expectations. This represents a meaningful shift in sentiment. The previous quarterly survey had shown industry expecting a decline in investment; the spring 2026 reading reverses that signal.
The investment intentions are distributed unevenly across sectors. Within industry, the expectations are shaped by the ongoing expansion of pharmaceutical production capacity — which requires substantial capital expenditure — alongside growing defence-related manufacturing and energy sector investments. Outside the industrial core, the construction sector continues to face structural headwinds: residential building activity remains constrained by financing conditions, and the municipal investment climate is described as challenging.
Services firms broadly expect stable to slightly improved conditions, with the trade, transport, and accommodation segments reflecting the cross-currents of decent consumer spending on one side and cost pressure from energy and logistics on the other.
Perhaps the most alarming single data point to emerge from Danmarks Statistik’s recent business surveys concerns Danish industry’s exposure to US trade policy. According to the barometer, 71 percent of industrial firms expect to be affected to a greater or lesser degree by the US trade war. More specifically, 66 percent say they anticipate being affected by increased tariffs on exports to the United States.
For a country as export-oriented as Denmark — and one in which the pharmaceutical sector generates enormous US revenues — this is a figure with real economic significance. Novo Nordisk’s US market exposure is well documented. But the concern extends beyond pharma: Danish exporters of food products, industrial equipment, furniture, and specialty manufacturing are all contemplating how higher US tariff barriers will affect their competitive position in one of the world’s most important consumer markets.
The Danish government, like those of its Nordic neighbours, has sought to maintain constructive relations with the United States while cushioning its firms against the tariff impact. The 10 percent base tariff regime — which SSB’s Norwegian analysis also noted as potentially expiring in July 2026 — creates a cliff edge for planning purposes, as businesses cannot be certain whether current rates will be maintained, escalated, or replaced.
Perhaps the most alarming single data point to emerge from Danmarks Statistik’s recent business surveys concerns Danish industry’s exposure to US trade policy. According to the barometer, 71 percent of industrial firms expect to be affected to a greater or lesser degree by the US trade war. More specifically, 66 percent say they anticipate being affected by increased tariffs on exports to the United States.
For a country as export-oriented as Denmark — and one in which the pharmaceutical sector generates enormous US revenues — this is a figure with real economic significance. Novo Nordisk’s US market exposure is well documented. But the concern extends beyond pharma: Danish exporters of food products, industrial equipment, furniture, and specialty manufacturing are all contemplating how higher US tariff barriers will affect their competitive position in one of the world’s most important consumer markets.
The Danish government, like those of its Nordic neighbours, has sought to maintain constructive relations with the United States while cushioning its firms against the tariff impact. The 10 percent base tariff regime — which SSB’s Norwegian analysis also noted as potentially expiring in July 2026 — creates a cliff edge for planning purposes, as businesses cannot be certain whether current rates will be maintained, escalated, or replaced.
Denmark shares with several of its neighbours a persistent weakness in residential construction that has proved resistant to recovery. New home sales have remained low. Building permits are not pointing to an imminent recovery. And the financing conditions — interest rates that remain elevated relative to the peaks of the low-rate era — continue to weigh on developers’ calculations.
The most direct evidence of this pressure is in the investment data: residential investment has fallen sharply from its 2022 peak and has not recovered. Housing costs, however — particularly in Copenhagen and other urban centres — have continued to rise, driven by the same supply constraint that is limiting new construction. This price-quantity divergence is a characteristic feature of the Danish housing market’s recent years, and it has distributional consequences that affect younger buyers and renters disproportionately.
The public sector has partially offset weak private construction through increased spending on defence infrastructure, healthcare facilities, and energy transition-related projects. The Q4 2025 national accounts showed a remarkable 5.6 percent growth in public consumption — driven primarily by government purchases of goods and services, especially defence. This public demand is providing meaningful support to Danish construction and manufacturing at precisely the moment when private sector demand in those areas is weak.
Danish industry’s experience with labour market constraints has evolved significantly from the acute shortages of 2021 and 2022. According to Danmarks Statistik’s industrial barometer, the share of firms reporting that their production is limited by a shortage of labour has been declining steadily since those peak years. In November, just 6 percent of industrial firms cited labour shortage as a production constraint — a far cry from the double-digit rates of the post-pandemic tightening phase.
This easing reflects a combination of factors: slower demand growth requiring less labour expansion, some normalisation of labour supply, and a gradual adjustment of the workforce through both hiring and natural attrition. For most industrial sectors, labour availability is no longer the binding constraint it was two years ago — though specific technical specialisations, particularly in software, automation, and pharmaceutical production, continue to face genuine supply shortages.
The broader labour market remains tight by European standards. Danish unemployment has historically been among the lowest in the EU, and the current labour market — while not as strained as at its 2022 peak — continues to provide strong income support for Danish households, helping to sustain the private consumption that underpins the non-pharma economy.
Denmark enters the second half of 2026 with an economy that is, by the headline measures, performing well. GDP growth is strong, employment is stable, investment intentions are improving, and the fiscal position is solid. But the structural dependency on a single pharmaceutical company’s output — and the vulnerability to US policy decisions that a tariff-focused trade war creates — represent concentrations of risk that Danish policymakers are aware of but can do little to quickly diversify away from.
The lesson of the Danish data is one of the most instructive available in European economic statistics: aggregate GDP numbers can be deeply misleading when they are dominated by a single sector whose revenue swings are driven by global drug pricing, patent expirations, and clinical trial outcomes rather than domestic demand conditions. For the policy debate, for the labour market, for construction, and for the services sector, what matters is the economy that grows at 0.2 percent when Novo Nordisk is excluded — not the headline that leads the press release.
Denmark shares with several of its neighbours a persistent weakness in residential construction that has proved resistant to recovery. New home sales have remained low. Building permits are not pointing to an imminent recovery. And the financing conditions — interest rates that remain elevated relative to the peaks of the low-rate era — continue to weigh on developers’ calculations.
The most direct evidence of this pressure is in the investment data: residential investment has fallen sharply from its 2022 peak and has not recovered. Housing costs, however — particularly in Copenhagen and other urban centres — have continued to rise, driven by the same supply constraint that is limiting new construction. This price-quantity divergence is a characteristic feature of the Danish housing market’s recent years, and it has distributional consequences that affect younger buyers and renters disproportionately.
The public sector has partially offset weak private construction through increased spending on defence infrastructure, healthcare facilities, and energy transition-related projects. The Q4 2025 national accounts showed a remarkable 5.6 percent growth in public consumption — driven primarily by government purchases of goods and services, especially defence. This public demand is providing meaningful support to Danish construction and manufacturing at precisely the moment when private sector demand in those areas is weak.
Danish industry’s experience with labour market constraints has evolved significantly from the acute shortages of 2021 and 2022. According to Danmarks Statistik’s industrial barometer, the share of firms reporting that their production is limited by a shortage of labour has been declining steadily since those peak years. In November, just 6 percent of industrial firms cited labour shortage as a production constraint — a far cry from the double-digit rates of the post-pandemic tightening phase.
This easing reflects a combination of factors: slower demand growth requiring less labour expansion, some normalisation of labour supply, and a gradual adjustment of the workforce through both hiring and natural attrition. For most industrial sectors, labour availability is no longer the binding constraint it was two years ago — though specific technical specialisations, particularly in software, automation, and pharmaceutical production, continue to face genuine supply shortages.
The broader labour market remains tight by European standards. Danish unemployment has historically been among the lowest in the EU, and the current labour market — while not as strained as at its 2022 peak — continues to provide strong income support for Danish households, helping to sustain the private consumption that underpins the non-pharma economy.
Denmark enters the second half of 2026 with an economy that is, by the headline measures, performing well. GDP growth is strong, employment is stable, investment intentions are improving, and the fiscal position is solid. But the structural dependency on a single pharmaceutical company’s output — and the vulnerability to US policy decisions that a tariff-focused trade war creates — represent concentrations of risk that Danish policymakers are aware of but can do little to quickly diversify away from.
The lesson of the Danish data is one of the most instructive available in European economic statistics: aggregate GDP numbers can be deeply misleading when they are dominated by a single sector whose revenue swings are driven by global drug pricing, patent expirations, and clinical trial outcomes rather than domestic demand conditions. For the policy debate, for the labour market, for construction, and for the services sector, what matters is the economy that grows at 0.2 percent when Novo Nordisk is excluded — not the headline that leads the press release.
